Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma

Annals of Surgical Oncology

Volumn 20, Issue 9, 2013, Pages 3106-3111

  Gyorki, David E ^a   Yuan, Jianda ^a   Mu, Zhenyu ^a   Zaidi, Bushra ^a   Pulitzer, Melissa ^a   Busam, Klaus ^a   Brady, Mary S ^a   Coit, Daniel G ^a   Allison, James P ^d   Wolchok, Jedd D ^a,b,c   Ariyan, Charlotte E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; BLOOD; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COLITIS; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN CELL; MALE; METASTATIC MELANOMA; PHENOTYPE; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; PRURITUS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; WOUND COMPLICATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84881479734     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2999-1     Document Type: Conference Paper

References (22)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26.
3. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-47.
4. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
5. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 107(9):4275-80.
6. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008;105(8):3005-10.
7. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116(7):1935-45.
8. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012;13(1):e32-42.
9. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-13.
10. Yuan J, Page DB, Ku GY, et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun. 2010;10:1.
11. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861-71.
12. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
13. Morton DLM, N; Kashani-Sabet M, Thompson JF, Kelley MC, et al. Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastases (Suppl abstr 8534). vol 30. Chicago: American Society of Clinical Oncology (ASCO); 2012.
14. Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547-55.
15. Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG. Stage IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14(10):2847-53.
16. Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995;110(1):119-28, discussion 129.
17. Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer J. 2012;18(2):176-84.
18. Wong JH, Skinner KA, Kim KA, Foshag LJ, Morton DL. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery. 1993;113(4):389-94.
19. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20.
20. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757-61.
21. Fourcade J, Kudela P, Sun Z, et al. PD-1 is a regulator of NY-ESO-1-specific CD8 + T cell expansion in melanoma patients. J Immunol. 2009;182(9):5240-9.
22. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.